Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:10/22/2014)... Oct. 22, 2014  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... Chief Executive Officer, has been elected to the Company,s ... Steven G. Anderson , Executive Chairman of CryoLife, stated, ... to be an excellent leader who is well positioned ...
(Date:10/22/2014)... JERUSALEM , October 22, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused ... today reported positive top-line clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... United States under a U.S. Food ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
...  Global performance improvement solutions provider General Physics Corporation ... (NYSE: GPX ), today announced that its ... Award for Excellence in Marketing and Communications in the ... http://photos.prnewswire.com/prnh/20110404/MM77341LOGO-b ) The MarCom Awards is ...
... SAN FRANCISCO, Dec. 8, 2011 ClinStar, LLC , ... markets of Russia and Eastern Europe to the biopharmaceutical industry, ... Minutes series by Business Day TV hosted by Terry Bradshaw.  ... 10 to 15 years and over one billion dollars to launch ...
Cached Medicine Technology:GP's PerformTech Division Receives Prestigious MarCom Award 2GP's PerformTech Division Receives Prestigious MarCom Award 3ClinStar to Be Featured on Business Day TV With Terry Bradshaw 2
(Date:10/25/2014)... home safe and sound is one of the best Halloween ... costumes and goody bags have reflective strips that improve visibility ... at Meadowlands Hospital Medical Center in Secaucus, N.J. ... flame-resistant, Davis said. He offers these others tips: ... a small area of skin first to ensure it doesn,t ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... of transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) ... multidistrict litigation underway in U.S. District Court, Southern ... Motion for Summary Judgment on Punitive Damages in ... Florida plaintiffs. In a ruling issued on October ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... -- herpes simplex -- might increase the risk of Alzheimer,s ... being a carrier of certain antibodies to the virus can ... "The identification of a treatable cause [herpes simplex] of ... researcher Dr. Hugo Lovheim, an associate professor in the department ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Diabetic retinopathy is the most common disorder seen in diabetics. ... a person with diabetes develops diabetic retinopathy,// a major cause ... diabetes is responsible for 7 percent of legal blindness, making ... adults 22 to 70 years old. ,Researchers from the ...
... can block the death of brain cells in mice who ... (HD), which is a rare degenerative brain disorder //caused by ... may be one step closer to a treatment, according to ... treated with a bile acid known as tauroursodeoxycholic acid (TUDCA), ...
... shows people with diabetes who are in a happy ... unhappily married counterparts. Researchers from the State University of ... adults with diabetes who had been married for an ... insulin, were surveyed again two years after the initial ...
... the University in Boston, a person's degree of inhibition when ... tied to his or her likelihood of being overweight. The ... low-calorie foods--can help people who just can't seem to resist ... B. Roberts. The reasons why some people are able to ...
... According to a new study, it has been found ... as you age. Mental decline is not a specific part ... are typically living longer. The ability to know, think, learn ... of life and survival in older ages. Researchers from the ...
... cancer all over the world. More than 30,000 women ... breast cancer this year. Researchers now believe small family ... fueling this ever-growing epidemic.// ,Researchers from England ... information on breastfeeding and childbearing patterns. Together, the studies ...
Cached Medicine News:Health News:Stop and think before you eat 2Health News: Breastfeeding may decrease Breast Cancer Risk 2
The ultimate replacement device, the Contour MD ICD offers a maximum stored energy of 42 J. The device delivers high-energy defibrillation output and is ideal for patients with maximum energy defibri...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... catheters comprise the world's broadest line ... procedures. Their advanced catheter design and ... response with a soft, atraumatic tip. ... sizes, Supreme and Response catheters provide ...
Medicine Products: